Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Recommendation of “Buy” from Analysts

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has been assigned a consensus recommendation of “Buy” from the eleven brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $16.5556.

A number of equities analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Cantor Fitzgerald assumed coverage on Inventiva in a report on Friday, July 17th. They set an “overweight” rating on the stock.

Institutional Investors Weigh In On Inventiva

Several hedge funds and other institutional investors have recently bought and sold shares of IVA. Creative Planning purchased a new position in Inventiva during the second quarter worth about $32,000. Millennium Management LLC acquired a new stake in shares of Inventiva during the 3rd quarter worth approximately $649,000. NewEdge Advisors LLC acquired a new stake in shares of Inventiva during the 3rd quarter worth approximately $116,000. UBS Group AG raised its position in shares of Inventiva by 28,881.6% during the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after buying an additional 2,634,580 shares during the period. Finally, Simplify Asset Management Inc. purchased a new stake in shares of Inventiva during the 4th quarter valued at approximately $1,570,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Stock Down 0.6%

NASDAQ:IVA opened at $4.72 on Wednesday. Inventiva has a one year low of $3.35 and a one year high of $7.98. The stock has a 50 day moving average price of $4.15 and a 200 day moving average price of $5.22.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.